{
 "city": "Medicaid Pharmaceutical and Therapeutics Committee",
 "state": "LA",
 "page": "https://mytown.theboringparts.com/city/la-medicaid-pharmaceutical-and-therapeutics-committee-491/",
 "attribution": "MyTown / The Boring Parts — CC BY 4.0. Summaries AI-generated from official sources.",
 "license": "https://creativecommons.org/licenses/by/4.0/",
 "generated": "2026-08-05",
 "upcoming": [],
 "recent": [
  {
   "date": "2025-11-05",
   "body": "Medicaid Pharmaceutical and Therapeutics Committee",
   "headline": "Committee to review 60+ drug classes and 11 single drugs for Medicaid",
   "summary": "The Louisiana Medicaid Pharmaceutical and Therapeutics Committee will review therapeutic classes including Alzheimer's, antipsychotics, and oncology drugs, plus single-drug reviews for conditions like HIV/AIDS and migraine. The meeting includes public testimony and approval of prior minutes. The next meeting is proposed for May 2026.",
   "agenda_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingNotices/491_LA%20PT%20Agenda%20November%205%202025%20-draft.docx",
   "minutes_url": null,
   "source": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/viewBoard.cfm?board=491"
  },
  {
   "date": "2025-05-09",
   "body": "Medicaid Pharmaceutical and Therapeutics Committee",
   "headline": "Committee to review 100+ drug classes and single products for Medicaid coverage",
   "summary": "The Louisiana Medicaid Pharmaceutical and Therapeutics Committee will meet to review therapeutic class monographs and cost sheets for over 100 drug categories, including opioids, antibiotics, antivirals, and diabetes treatments. The committee will also consider several single products for conditions such as Parkinson's disease, antipsychotics, hemophilia, and oncology. Public testimony will be taken on the proposed reviews.",
   "agenda_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingNotices/491_PT_AgendaMay2025.docx",
   "minutes_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingMinutes/491_P&T%20Committee%20Meeting%20Minutes%20Apprived%20-05-09-25.pdf",
   "source": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/viewBoard.cfm?board=491"
  },
  {
   "date": "2024-10-30",
   "body": "Medicaid Pharmaceutical and Therapeutics Committee",
   "headline": "Committee to review dozens of drug classes for Medicaid coverage",
   "summary": "The Louisiana Medicaid Pharmaceutical and Therapeutics Committee will meet to review and potentially update the state's Preferred Drug List (PDL) by evaluating numerous therapeutic classes and single drugs. The agenda includes public testimony on Alzheimer's, antidepressants, antipsychotics, oncology, and other agents, as well as brand vs. generic drug reviews. The committee will also discuss meeting minutes, ethics, and a virtual review process.",
   "agenda_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingNotices/491_LA%20PT%20Agenda%20October%2030.2024.docx",
   "minutes_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingMinutes/491_P&T%20Committee%20Meeting%20Minutes%20Approved%20-10302024.pdf",
   "source": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/viewBoard.cfm?board=491"
  },
  {
   "date": "2024-04-26",
   "body": "Medicaid Pharmaceutical and Therapeutics Committee",
   "headline": null,
   "summary": null,
   "agenda_url": null,
   "minutes_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingMinutes/491_P_T%20Committee%20Meeting%20Minutes%20Approved%20~%204_26_24.pdf",
   "source": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/viewBoard.cfm?board=491"
  },
  {
   "date": "2023-10-27",
   "body": "Medicaid Pharmaceutical and Therapeutics Committee",
   "headline": "Medicaid Committee to review 69 drug classes and 11 single drugs",
   "summary": "The Medicaid Pharmaceutical and Therapeutics Committee is meeting to conduct therapeutic class reviews and hear manufacturer testimony. The body will also review 11 specific drugs for potential inclusion or modification. These reviews determine which medications are covered under the state's Medicaid program.",
   "agenda_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingNotices/491_PT%20Agenda%20Oct.27.2023%20Final.pdf",
   "minutes_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingMinutes/491_P_T%20Committee%20Meeting%20Minutes%20Approved~%2010_27_23.pdf",
   "source": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/viewBoard.cfm?board=491"
  },
  {
   "date": "2023-05-05",
   "body": "Medicaid Pharmaceutical and Therapeutics Committee",
   "headline": "Medicaid Committee to review drug classes and specific medications",
   "summary": "The Medicaid Pharmaceutical and Therapeutics Committee is meeting to conduct therapeutic class reviews and evaluate specific drugs for the Preferred Drug List. The body will hear testimony from drug manufacturers and review cost sheets and monographs.",
   "agenda_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingNotices/491_LA%20PT%20Agenda%20May5.2023%20Final.pdf",
   "minutes_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingMinutes/491_P_T%20Committee%20Meeting%20Minutes%20Approved~%205_5_23.pdf",
   "source": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/viewBoard.cfm?board=491"
  },
  {
   "date": "2022-11-04",
   "body": "Medicaid Pharmaceutical and Therapeutics Committee",
   "headline": "Medicaid Committee reviews drug classes and specific medications",
   "summary": "The Medicaid Pharmaceutical and Therapeutics Committee is meeting to conduct therapeutic class reviews and single drug reviews. The agenda includes the election of a chairman and co-chairman, as well as discussions on various drug categories and specific new medications.",
   "agenda_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingNotices/491_PT%20Agenda%20Nov2022%20DRAFT.docx.pdf",
   "minutes_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingMinutes/491_P_T%20Committee%20Meeting%20Minutes%20Approved%20~%2011_4_22.pdf",
   "source": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/viewBoard.cfm?board=491"
  },
  {
   "date": "2022-05-06",
   "body": "Medicaid Pharmaceutical and Therapeutics Committee",
   "headline": "Medicaid Committee to review 65 drug classes and 10 single drugs",
   "summary": "The Louisiana Department of Health Medicaid Pharmaceutical and Therapeutics Committee is conducting a virtual review of drug classes and specific medications. The body will discuss therapeutic class reviews, single drug reviews, and brand-over-generic changes to the Preferred Drug List.",
   "agenda_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingNotices/491_PT%20Agenda%20May6.2022.pdf",
   "minutes_url": null,
   "source": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/viewBoard.cfm?board=491"
  },
  {
   "date": "2021-11-03",
   "body": "Medicaid Pharmaceutical and Therapeutics Committee",
   "headline": "Medicaid Committee to review 65 drug classes and 9 specific medications",
   "summary": "The Medicaid Pharmaceutical and Therapeutics Committee is meeting to conduct therapeutic class reviews and individual drug reviews. The body will hear manufacturer testimony and review the Preferred Drug List reflecting Spring 2021 recommendations.",
   "agenda_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingNotices/491_PT%20Agenda%20Nov2021%20DRAFT.pdf",
   "minutes_url": null,
   "source": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/viewBoard.cfm?board=491"
  },
  {
   "date": "2021-05-07",
   "body": "Medicaid Pharmaceutical and Therapeutics Committee",
   "headline": "Medicaid Committee reviews drug classes and specific medications",
   "summary": "The Medicaid Pharmaceutical and Therapeutics Committee is conducting a virtual review of various therapeutic drug classes. The agenda includes reports on prior authorizations and the Preferred Drug List, alongside reviews of several individual drugs.",
   "agenda_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingNotices/491_PT%20Agenda%20May2021%20DRAFT.docx",
   "minutes_url": null,
   "source": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/viewBoard.cfm?board=491"
  },
  {
   "date": "2020-10-28",
   "body": "Medicaid Pharmaceutical and Therapeutics Committee",
   "headline": "No Medicaid Pharmaceutical and Therapeutics Committee meeting scheduled for October 2020",
   "summary": "The Louisiana Department of Health announced that there will be no fall P&T Committee meeting due to the ongoing COVID-19 pandemic. The new Preferred Drug List (PDL) is scheduled to be posted by January 1, 2021.",
   "agenda_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingNotices/491_No%20Meeting%20Notification.pdf",
   "minutes_url": null,
   "source": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/viewBoard.cfm?board=491"
  },
  {
   "date": "2019-11-06",
   "body": "Medicaid Pharmaceutical and Therapeutics Committee",
   "headline": "Medicaid Committee to review 54 drug classes and 7 single drugs",
   "summary": "The Medicaid Pharmaceutical and Therapeutics Committee is meeting to conduct therapeutic class reviews and single drug reviews. The body will also consider proposed amendments to the P&T Bylaws.",
   "agenda_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingNotices/491_P&T%20Agenda%20Nov.6.2019%20Final.pdf",
   "minutes_url": null,
   "source": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/viewBoard.cfm?board=491"
  },
  {
   "date": "2019-04-26",
   "body": "Medicaid Pharmaceutical and Therapeutics Committee",
   "headline": "Committee to review 68 drug classes and 9 new drugs for Medicaid formulary",
   "summary": "The Louisiana Medicaid Pharmaceutical and Therapeutics Committee will meet to review and potentially update the state's Medicaid preferred drug list. The agenda includes evaluations of 68 therapeutic drug classes, ranging from acne agents to hepatitis C treatments, as well as nine new single-drug reviews. The committee will also consider prior authorization reports and hear public testimony.",
   "agenda_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingNotices/491_PT%20Agenda%20April26.2019%20Final.pdf",
   "minutes_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingMinutes/491_P&T%20Minutes%20April%2026.2019%20Signed.pdf",
   "source": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/viewBoard.cfm?board=491"
  },
  {
   "date": "2018-11-02",
   "body": "Medicaid Pharmaceutical and Therapeutics Committee",
   "headline": "Medicaid Committee to review drug classes and specific medications",
   "summary": "The Medicaid Pharmaceutical and Therapeutics Committee is meeting to conduct therapeutic class reviews and individual drug reviews. The body will discuss drug manufacturer testimony and review the Preferred Drug List (PDL).",
   "agenda_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingNotices/491_PT%20Draft%20Agenda%20Nov.2.2018.pdf",
   "minutes_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingMinutes/491_P&T%20%20Nov.2.2018%20Minutes%20SignedApril26.2019.pdf",
   "source": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/viewBoard.cfm?board=491"
  },
  {
   "date": "2018-05-04",
   "body": "Medicaid Pharmaceutical and Therapeutics Committee",
   "headline": "Medicaid P&T Committee to review drug classes and single drug additions",
   "summary": "The Louisiana Department of Health Medicaid Pharmaceutical and Therapeutics Committee is meeting to review therapeutic drug classes and individual medications. The body will discuss drug manufacturer testimony and evaluate specific drugs for the Preferred Drug List.",
   "agenda_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingNotices/491_PT%20Agenda%20May4.2018%20Draft.pdf",
   "minutes_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingMinutes/491_LA_PT%20Meeting%20Minutes_04May2018.pdf",
   "source": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/viewBoard.cfm?board=491"
  },
  {
   "date": "2017-04-26",
   "body": "Medicaid Pharmaceutical and Therapeutics Committee",
   "headline": "Medicaid Committee to review numerous drug classes and single drug applications",
   "summary": "The Medicaid Pharmaceutical and Therapeutics Committee is meeting to conduct therapeutic class reviews and evaluate specific new drug applications. The body will also review a monthly prior authorization report and the results of the Preferred Drug List program.",
   "agenda_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingNotices/491_PT%20Agenda%20April26%202017%20Final.pdf",
   "minutes_url": null,
   "source": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/viewBoard.cfm?board=491"
  },
  {
   "date": "2016-11-02",
   "body": "Medicaid Pharmaceutical and Therapeutics Committee",
   "headline": "Committee to review 41 drug classes and 16 new single drugs for Medicaid coverage",
   "summary": "The Louisiana Medicaid Pharmaceutical and Therapeutics Committee will review 41 therapeutic drug classes and 16 new single drug applications, including treatments for Alzheimer's, hepatitis C, and multiple sclerosis. The committee will also consider prior authorization reports and the preferred drug list from the previous meeting. Public testimony will be heard.",
   "agenda_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingNotices/491_P&T%20Agenda%20Nov.2.2016%20Draft.pdf",
   "minutes_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingMinutes/491_LA_PT_Meeting_Minutes_02NOV2016.pdf",
   "source": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/viewBoard.cfm?board=491"
  },
  {
   "date": "2016-05-04",
   "body": "Medicaid Pharmaceutical and Therapeutics Committee",
   "headline": "Committee to review 51 drug classes and 13 new single drugs for Medicaid formulary",
   "summary": "The Louisiana Medicaid Pharmaceutical and Therapeutics Committee will meet to review therapeutic drug classes and consider adding new single drugs to the preferred drug list. The agenda includes approval of prior meeting minutes, a proposed bylaw amendment, and public testimony. This meeting determines which medications are covered by Louisiana Medicaid.",
   "agenda_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingNotices/491_PT%20Agenda%20May4%202016%20Draft.pdf",
   "minutes_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingMinutes/491_May2016%20Minutes%20Appr%20Nov2016.pdf",
   "source": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/viewBoard.cfm?board=491"
  },
  {
   "date": "2015-10-28",
   "body": "Medicaid Pharmaceutical and Therapeutics Committee",
   "headline": "Medicaid P&T Committee to review drug classes and single drug additions",
   "summary": "The committee is reviewing therapeutic drug classes and considering the addition of 60 specific drugs to the Preferred Drug List. The meeting includes reports on prior authorizations and managed care updates.",
   "agenda_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingNotices/491_PT%20Agenda%20Oct28%202015%20Draft%2010%2027.%2015.pdf",
   "minutes_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingMinutes/491_Oct2015%20Minutes%20Sigend%20may4.2016.pdf",
   "source": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/viewBoard.cfm?board=491"
  },
  {
   "date": "2015-05-06",
   "body": "Medicaid Pharmaceutical and Therapeutics Committee",
   "headline": "Committee to review numerous drug classes and single medications",
   "summary": "The Medicaid Pharmaceutical and Therapeutics Committee will conduct reviews of various therapeutic drug classes and specific individual drugs. The meeting also includes updates on managed care and reports on the Louisiana Medicaid Preferred Drug List.",
   "agenda_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingNotices/491_P&T%20Draft%20Agenda%20May2015.pdf",
   "minutes_url": null,
   "source": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/viewBoard.cfm?board=491"
  },
  {
   "date": "2014-10-29",
   "body": "Medicaid Pharmaceutical and Therapeutics Committee",
   "headline": "Medicaid P&T Committee to review drug classes and new medications",
   "summary": "The Medicaid Pharmaceutical and Therapeutics Committee is meeting to review therapeutic drug classes and hear manufacturer testimony. The body will also evaluate several new single drug reviews for inclusion in current Preferred Drug List categories.",
   "agenda_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingNotices/491_P&T%20Draft%20Agenda%20Oct.29.2014.pdf",
   "minutes_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingMinutes/491_Oct.29.2014%20P&T%20Minutes%20Signed%2010.28.2015.pdf",
   "source": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/viewBoard.cfm?board=491"
  },
  {
   "date": "2014-04-30",
   "body": "Medicaid Pharmaceutical and Therapeutics Committee",
   "headline": "Medicaid P&T Committee to review therapeutic drug classes and new drug requests",
   "summary": "The Medicaid Pharmaceutical and Therapeutics Committee is meeting to review 46 therapeutic drug classes and hear manufacturer testimony. The body will also consider six new single drug reviews for the current Preferred Drug List (PDL).",
   "agenda_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingNotices/491_P&T%20DraftAgenda%20April30.2014.pdf",
   "minutes_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingMinutes/491_May2014%20P&T%20Minutes%20Signed%20Oct.29.2014.pdf",
   "source": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/viewBoard.cfm?board=491"
  },
  {
   "date": "2013-11-06",
   "body": "Medicaid Pharmaceutical and Therapeutics Committee",
   "headline": "Committee reviews numerous drug classes and single drug updates",
   "summary": "The Medicaid Pharmaceutical and Therapeutics Committee is meeting to conduct therapeutic class reviews and evaluate new single drug reviews for the Preferred Drug List. The agenda also includes an ethics review, committee overview, and reports on prior authorization and travel regulations.",
   "agenda_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingNotices/491_P&T%20DraftAgenda%20Nov.6.2013.pdf",
   "minutes_url": null,
   "source": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/viewBoard.cfm?board=491"
  },
  {
   "date": "2013-05-08",
   "body": "Medicaid Pharmaceutical and Therapeutics Committee",
   "headline": "Committee to review 44 drug classes and 8 new drugs for Medicaid coverage",
   "summary": "The Louisiana Medicaid Pharmaceutical and Therapeutics Committee is meeting to review and potentially update the Preferred Drug List. The agenda includes consideration of 44 therapeutic drug classes and 8 new single drug products. Reports from the prior authorization process and a provider synergies annual report will also be discussed.",
   "agenda_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingNotices/491_P&T%20Agenda%20May%208.2013%20Final.pdf",
   "minutes_url": null,
   "source": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/viewBoard.cfm?board=491"
  },
  {
   "date": "2012-10-31",
   "body": "Medicaid Pharmaceutical and Therapeutics Committee",
   "headline": "LA Medicaid P&T Committee reviews 35 therapeutic classes and 6 new drugs",
   "summary": "The Louisiana Medicaid Pharmaceutical and Therapeutics Committee will review and potentially update the Preferred Drug List (PDL) by considering 35 therapeutic class reviews, including new classes like sympatholytic antihypertensives and topical antipsoriatics. The committee will also evaluate six new single drugs for inclusion in existing PDL categories, such as Bydureon and Omontys. Additionally, they will discuss pharmacy reimbursement changes and incorporation of pharmacy into managed care.",
   "agenda_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingNotices/491_Final%20P&T%20Agenda%20Oct31.2012.pdf",
   "minutes_url": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/MeetingMinutes/491_May2.2012%20Min%20ApprOct31.20121.pdf",
   "source": "https://wwwcfprd.doa.louisiana.gov/boardsandcommissions/viewBoard.cfm?board=491"
  }
 ]
}